Breast cancer prevention: SERMs come of age
A partir des données de 9 essais incluant au total 83 399 participantes (durée médiane de suivi : 65 mois), cette méta-analyse évalue l'effet de modulateurs sélectifs des récepteurs aux œstrogènes sur l'incidence de cancer du sein
In The Lancet , Jack Cuzick and colleagues 1 present an overview of nine trials of selective oestrogen receptor modulators (SERMs) for breast cancer prevention, the results of more than a quarter of a century of research. So far, four types of SERM have been tested in randomised controlled trials: tamoxifen, raloxifene, lasofoxifene, and arzoxifene. The drugs were tested in women who mostly had an increased risk of developing breast cancer, or who had osteoporosis, to test reduction in fracture risk...
The Lancet , commentaire, 2012